Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + docetaxel + carboplatin neoadjuvant study in HER2-positive breast cancer
ChiCTR2000039286Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib, trastuzumab, docetaxel and carboplatin in breast cancer, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Pathologic complete response. Started Oct 2020; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000039286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039286.